The ART1 Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the ART1 gene in the human esophageal squamous cell carcinoma line KYSE-30. This product comprises a mixed population of edited cells with heterogeneous ART1 gene modifications, providing a versatile loss-of-function model that circumvents the need for clonal isolation.
The KYSE-30 cell line is a well-characterized, well-differentiated human esophageal squamous cell carcinoma line derived from a primary tumor. It retains key features of malignant esophageal epithelial cells and is widely employed in cancer research for studying tumor biology, drug response, and oncogenic signaling pathways. This adherent epithelial line provides a physiologically relevant platform for investigating molecular mechanisms underlying esophageal squamous cell carcinoma progression.
ART1 encodes a mono-ADP-ribosyltransferase that catalyzes the transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD+) onto arginine residues of target proteins, including histones H3R2, H3R8, and H4R3, as well as various cell surface receptors and signaling molecules. This post-translational modification modulates protein function, chromatin structure, DNA repair, and transcriptional regulation. ART1 activity is stimulated by upstream inflammatory signals such as interferon-gamma (IFN-??), interleukin-6 (IL-6), and STAT3, and can be engaged downstream of epidermal growth factor receptor (EGFR) activation. It functions in concert with PARP1/2 and ADP-ribosylhydrolases (e.g., PARG), which collectively govern the dynamic equilibrium of cellular ADP-ribosylation. Through histone ADP-ribosylation, ART1 influences chromatin remodeling and gene expression, thereby contributing to DNA damage response pathways and immune signaling processes.
In the context of esophageal squamous cell carcinoma, ART1-mediated ADP-ribosylation may play a critical role in modulating tumor growth, DNA damage repair capacity, and immune evasion. Dysregulation of ADP-ribosylation pathways has been implicated in various cancers, and targeting ART1 activity could reveal novel vulnerabilities in esophageal cancer cells. The KYSE-30 ART1 knockout polyclonal cells enable dissection of ART1-dependent mechanisms in a disease-relevant cellular environment, facilitating studies that connect protein modification dynamics to malignant phenotypes.
These polyclonal knockout cells are suitable for a range of applications including analysis of ADP-ribosylation by western blotting, RT-qPCR assessment of ART1 transcript levels, immunofluorescence detection of histone ADP-ribosylation marks, chromatin immunoprecipitation (ChIP)-qPCR for histone modifications, flow cytometry for cell-surface ADP-ribosylation, cell migration and invasion assays, drug sensitivity profiling, and NAD+ metabolism studies. They serve as a powerful tool for cancer cell biology, signal transduction research, and validation of pharmacological targets. For additional technical specifications and support, please contact Ascent Research.
